NCT00003897View on ClinicalTrials.gov

Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 1999

Primary Completion Date

March 31, 2001

Study Completion Date

December 31, 2006

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

gp100 antigen

BIOLOGICAL

sargramostim

Trial Locations (1)

53792

University of Wisconsin Comprehensive Cancer Center, Madison

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Wisconsin, Madison

OTHER

NCT00003897 - Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma | Biotech Hunter | Biotech Hunter